165 related articles for article (PubMed ID: 12485205)
21. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Kayser V; Aubel B; Hamon M; Bourgoin S
Br J Pharmacol; 2002 Dec; 137(8):1287-97. PubMed ID: 12466238
[TBL] [Abstract][Full Text] [Related]
22. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Hoskin KL; Goadsby PJ
Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
[TBL] [Abstract][Full Text] [Related]
23. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
24. Effects of subcutaneous sumatriptan on plasma growth hormone concentrations in migraine patients.
Pinessi L; Rainero I; Savi L; Valfrè W; Limone P; Calvelli P; Del Rizzo P; Gianotti L; Taliano M; Ghigo E; Arvat E
Cephalalgia; 2000 May; 20(4):223-7. PubMed ID: 10999671
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
27. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat.
Storer RJ; Goadsby PJ
Brain; 1997 Dec; 120 ( Pt 12)():2171-7. PubMed ID: 9448572
[TBL] [Abstract][Full Text] [Related]
28. Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes.
Sánchez-López A; Centurión D; Vázquez E; Arulmani U; Saxena PR; Villalón CM
Naunyn Schmiedebergs Arch Pharmacol; 2004 Feb; 369(2):220-7. PubMed ID: 14673512
[TBL] [Abstract][Full Text] [Related]
29. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
[TBL] [Abstract][Full Text] [Related]
30. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization.
van den Broek RW; Bhalla P; VanDenBrink AM; de Vries R; Sharma HS; Saxena PR
Cephalalgia; 2002 Mar; 22(2):83-93. PubMed ID: 11972574
[TBL] [Abstract][Full Text] [Related]
31. Functional profile of almotriptan in animal models predictive of antimigraine activity.
Gras J; Bou J; Llenas J; Fernández AG; Palacios JM
Eur J Pharmacol; 2000 Dec; 410(1):43-51. PubMed ID: 11134655
[TBL] [Abstract][Full Text] [Related]
32. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
Yu XJ; Waeber C; Castanon N; Scearce K; Hen R; Macor JE; Chauveau J; Moskowitz MA
Mol Pharmacol; 1996 May; 49(5):761-5. PubMed ID: 8622623
[TBL] [Abstract][Full Text] [Related]
33. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
34. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
Tfelt-Hansen P; De Vries P; Saxena PR
Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
[TBL] [Abstract][Full Text] [Related]
35. Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model.
McCall RB
Brain Res; 1997 Nov; 775(1-2):189-92. PubMed ID: 9439842
[TBL] [Abstract][Full Text] [Related]
36. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Jandu KS; Barrett V; Brockwell M; Cambridge D; Farrant DR; Foster C; Giles H; Glen RC; Hill AP; Hobbs H; Honey A; Martin GR; Salmon J; Smith D; Woollard P; Selwood DL
J Med Chem; 2001 Mar; 44(5):681-93. PubMed ID: 11262079
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors.
Goadsby PJ; Knight Y
Br J Pharmacol; 1997 Nov; 122(5):918-22. PubMed ID: 9384509
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses.
De Vries P; Willems EW; Heiligers JP; Villalón CM; Saxena PR
Br J Pharmacol; 1999 May; 127(2):405-12. PubMed ID: 10385240
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
